Does Rallies show TNXP price targets?

Yes. Rallies tracks TNXP analyst ratings, consensus rating, average price target, upgrades, downgrades, analyst firms, and recent price target changes when available.

Is TNXP research on Rallies investment advice?

No. Rallies provides research, data, and educational context for TNXP. It does not provide personalized investment advice.

TNXP (Tonix Pharmaceuticals Holding Corp.) Stock Analysis - Analyst Ratings

Tonix Pharmaceuticals Holding Corp. (TNXP) is a publicly traded Healthcare sector company. As of May 21, 2026, TNXP trades at $14.21 with a market cap of $227.32M and a P/E ratio of -0.99. TNXP moved +5.47% today. Year to date, TNXP is -4.73%; over the trailing twelve months it is -51.51%. Its 52-week range spans $6.76 to $130.00. Analyst consensus is strong buy with an average price target of $41.33. Rallies surfaces TNXP's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

What do analysts rate TNXP?

3 analysts cover TNXP: 0 strong buy, 3 buy, 0 hold, 0 sell, and 0 strong sell. The consensus rating is strong buy. The average price target is $41.33.

TNXP Key Metrics

Key financial metrics for TNXP
Metric	Value
Price	$14.21
Market Cap	$227.32M
P/E Ratio	-0.99
EPS	$-14.53
Dividend Yield	0.00%
52-Week High	$130.00
52-Week Low	$6.76
Volume	302
Avg Volume	0
Revenue (TTM)	$17.56M
Net Income	$-147.39M
Gross Margin	58.56%

TNXP Analyst Consensus

3 analysts cover TNXP: 0 strong buy, 3 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $41.33.

Latest TNXP News

Tonix to Unveil April 2021–2024 Fibromyalgia Claims Data at ISPOR 2026 — May 14, 2026
Tonix Reports 2,145 Prescribers, 5,400 Q1 Prescriptions; Secures 35M-Lives GPO Deal — May 11, 2026
Tonix’s TNX-1700 Reverses Aged Gastric Tumors, TNX-4700 Shows Potent BTLA Antagonism — Apr 23, 2026
Tonix Reports Higher Bioavailability and Two-Hour Faster tmax for TONMYA Sublingual vs Oral ER — Apr 15, 2026
Tonix’s TNX-4800 Shows 62–69 Day Half-Life, Plans 350 mg Adaptive Phase 2 in H1 2027 — Mar 31, 2026

Recent TNXP Insider Trades

LEDERMAN SETH bought 5.00K (~$63.10K) on Mar 31, 2026.
LEDERMAN SETH bought 15.00K (~$223.35K) on Mar 18, 2026.
Taylor Carolyn E. bought 418 (~$15.06K) on Aug 21, 2025.

Common questions about TNXP

What do analysts rate TNXP?: 3 analysts cover TNXP: 0 strong buy, 3 buy, 0 hold, 0 sell, and 0 strong sell. The consensus rating is strong buy. The average price target is $41.33.
Does Rallies show TNXP price targets?: Yes. Rallies tracks TNXP analyst ratings, consensus rating, average price target, upgrades, downgrades, analyst firms, and recent price target changes when available.
Is TNXP research on Rallies investment advice?: No. Rallies provides research, data, and educational context for TNXP. It does not provide personalized investment advice.